Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.    Read More

Stacy and Clinton definitely had nothing to do with it, but Sanofi-Pasteur (the vaccines division of Sanofi-Aventis) greets visitors with a "What Not To Wear" brochure.    Read More

I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck.    Read More

Pfizer, or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman.   Read More

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.    Read More

On a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck and the company it's buying, Schering-Plough, are sliding. So, what gives?    Read More

GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.    Read More

Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.   Read More

I'm about to head out to my 30th high school reunion in L.A. this weekend. 30 years! Impossible. Seems like only yesterday that I saw my parents off to their 25th.    Read More